<DOC>
	<DOCNO>NCT00297258</DOCNO>
	<brief_summary>The purpose study evaluate activity tolerability pazopanib subject advance and/or metastatic soft tissue sarcoma relapse follow standard therapy standard therapy exists characterize pharmacokinetics pazopanib subject population .</brief_summary>
	<brief_title>Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Histological evidence high intermediate grade malignant soft tissue sarcoma , cytological evidence case presence multiple metastasis . List eligible ineligible tumour include protocol . Formalin fix paraffin embed tumour block representative H/E ( haematoxylin/eosin ) slide must available histological central review . Histological central review require treatment start mandatory within 3 month registration . Local histopathological diagnosis accept entry study . Presence measurable disease ( accord RECIST criterion ) . Relapsed refractory disease incurable surgery radiotherapy . Evidence objective progression within last 6 month ( RECIST ) document measurement disease , Patients must either eligible chemotherapy ( instance age , biological condition , patientrefusal ) must receive one combination two single agent chemotherapy regimen advance disease ; ( neo ) adjuvant therapy count towards requirement . At least 18 year age WHO performance status 0 1 Adequate bone marrow function Adequate hepatic function Adequate renal function PT / PTT le 1.2 x UNL . LVEF low limit normal institution , base ECHO MUGA Able swallow retain oral medication Women childbearing potential agree use contraceptive method ( Oral contraceptive allow ) . Absence serious and/or unstable preexist medical , psychiatric condition ( include lab abnormality ) could interfere patient safety obtain informed consent . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition assess patient registration trial . Written informed consent give accord ICH/GCP , national/local regulation patient registration/randomization . history leptomeningeal brain metastasis history malignancy sarcoma ( except basal cell squamous cell carcinoma skin , carcinoma situ cervix breast , patient free malignancy great 3 year ) . Class II , III IV heart failure ( NYHA classification ) . A patient history class II heart failure asymptomatic treatment may consider eligible . Arterial venous thrombosis , myocardial infarction , unstable angina , cardiac angioplasty stenting within last 3 month Uncontrolled poorly control hypertension . Initiation adjustment BP medication permit prior study entry , provide patient 3 consecutive BP reading less 150 / 90 mm Hg separate minimum 24 hr . These reading need collect prior registration study . Women childbearing potential , pregnant ( negative serum pregnancy test entry ) lactating . Therapeutic dose warfarin . Low molecular weight heparin prophylactic low dose warfarin permit . PT/INR PPT must meet inclusion criterion . Concurrent therapy specifically prohibit medication requirement use medication treatment pazopanib Major surgery , hormonal therapy ( replacement ) , chemotherapy radiotherapy , immunotherapy investigational agent within last 28 day and/or recover prior therapy within last 28 day . Use erythropoietin consider supportive care permit . The patient recover prior surgery open wound . History malabsorption syndrome , disease significantly affect gastrointestinal function major resection stomach small bowel could affect absorption , distribution , metabolism excretion study drug . No unresolved bowel obstruction diarrhea .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>Synovial sarcoma</keyword>
	<keyword>Pazopanib ( GW786034 )</keyword>
	<keyword>Adipocytic tumor</keyword>
	<keyword>Leiomyosarcoma</keyword>
	<keyword>Phase II</keyword>
</DOC>